| 臺大學術典藏 |
2020-03-06T05:26:22Z |
Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment
|
Chung K.-P.; Huang Y.-T.; YIH-LEONG CHANG; Yu C.-J.; Yang C.-H.; Chang Y.-C.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:21Z |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer
|
Tsai T.-H.; Su K.-Y.; Wu S.-G.; YIH-LEONG CHANG; Luo S.-C.; Jane I.-S.; Yu C.-J.; Yue S.-L.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:19Z |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
|
Wu S.-G.; Hu F.-C.; YIH-LEONG CHANG; Lee Y.-C.; Yu C.-J.; Chang Y.-C.; Wu J.-Y.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:17Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; Hsieh M.-S.; Wu S.-G.; YIH-LEONG CHANG; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:09Z |
The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
|
Wu S-G.; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Yang J.C.-H.; Wen Y.-F.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:07Z |
The role of PIK3CA mutations among lung adenocarcinoma patients with primary and acquired resistance to EGFR tyrosine kinase inhibition
|
Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:05Z |
Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
|
Wu S.-G.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; YIH-LEONG CHANG; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-06T05:26:04Z |
Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression
|
Chen C.-Y.; Chen Y.-Y.; Chen J.J.W.; Chen K.-Y.; Ho C.-C.; Shih J.-Y.; YIH-LEONG CHANG; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-06T05:26:03Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; YIH-LEONG CHANG; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-06T05:26:02Z |
IGFBP7 Drives resistance to epidermal growth factor receptor tyrosine kinase inhibition in lung cancer
|
Wu S.-G.; Chang T.-H.; Tsai M.-F.; Liu Y.-N.; Hsu C.-L.; YIH-LEONG CHANG; Yu C.-J.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-06T05:26:00Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; YIH-LEONG CHANG; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T08:16:44Z |
Overexpression of Placenta Growth Factor Contributes to the Pathogenesis of Pulmonary Emphysema
|
Tsao P.-N.;Su Y.-N.;Li H.;Pei-Hsin Huang;Chien C.-T.;Lai Y.-L.;Lee C.-N.;Chen C.-A.;Cheng W.-F.;Wei S.-C.;Yu C.-J.;Hsieh F.-J.;Hsu S.-M.; Tsao P.-N.; Su Y.-N.; Li H.; PEI-HSIN HUANG; Chien C.-T.; Lai Y.-L.; Lee C.-N.; Chen C.-A.; Cheng W.-F.; Wei S.-C.; Yu C.-J.; Hsieh F.-J.; Hsu S.-M. |
| 臺大學術典藏 |
2020-03-05T08:04:11Z |
Clinical and the prognostic characteristics of lung adenocarcinoma patients with ros1 fusion in comparison with other driver mutations in east asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Shih J.-Y.; Liu Y.-N.; Tsai M.-F.; Tsai T.-H.; Yu C.-J.; Yang J.C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2020-03-05T08:04:09Z |
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion
|
Tsai T.-H.; Wu S.-G.; MIN-SHU HSIEH; Yu C.-J.; Yang J.C.H.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:08Z |
Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations
|
Chen Y.-F.; MIN-SHU HSIEH; Wu S.-G.; Chang Y.-L.; Yu C.-J.; Yang J.C.-H.; Yang P.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Expression of notch gene and its impact on survival of patients with resectable non-small cell lung cancer
|
Chen C.-Y.;Chen Y.-Y.;Min-Shu Hsieh;Ho C.-C.;Chen K.-Y.;Shih J.-Y.;Yu C.-J.; Chen C.-Y.; Chen Y.-Y.; MIN-SHU HSIEH; Ho C.-C.; Chen K.-Y.; Shih J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2020-03-05T08:04:02Z |
Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma
|
Chang L.-C.;Chen K.-Y.;Shih J.-Y.;Yu C.-J.;Min-Shu Hsieh; Chang L.-C.; Chen K.-Y.; Shih J.-Y.; Yu C.-J.; MIN-SHU HSIEH |
| 臺大學術典藏 |
2020-03-05T08:04:01Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; Lee J.-H.; Tsai T.-H.; Su K.-Y.; MIN-SHU HSIEH; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H.; Lin C.-C.;Shih J.-Y.;Yu C.-J.;Ho C.-C.;Liao W.-Y.;Lee J.-H.;Tsai T.-H.;Su K.-Y.;Min-Shu Hsieh;Chang Y.-L.;Bai Y.-Y.;Huang D.D.-R.;Thress K.S.;Yang J.C.-H. |
| 臺大學術典藏 |
2020-03-04T09:03:20Z |
Statins do not improve short-term survival in an oriental population with sepsis
|
Yang K.-C.;Chien J.-Y.;Tseng W.-K.;Hsueh P.-R.;Yu C.-J.;Chau-Chung Wu; Yang K.-C.; Chien J.-Y.; Tseng W.-K.; Hsueh P.-R.; Yu C.-J.; CHAU-CHUNG WU |
| 臺大學術典藏 |
2020-03-03T03:06:39Z |
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin
|
Chang Y.-C.; Yu C.-J.; Chen C.-M.; Hu F.-C.; Hsu H.-H.; WEN-YIH TSENG; Ting-Fang Shih T.; Yang P.-C.; Chih-Hsin Yang J. |
| 臺大學術典藏 |
2020-03-02T06:40:01Z |
Dynamic dispatching and preventive maintenance for parallel machines with dispatching-dependent deterioration
|
Wu, C.-H.;Yao, Y.-C.;Dauz?re-P?r?s, S.;Yu, C.-J.; Wu, C.-H.; Yao, Y.-C.; Dauz?re-P?r?s, S.; Yu, C.-J.; CHENG-HUNG WU |
| 臺大學術典藏 |
2020-03-02T06:40:01Z |
Dynamic dispatching for re-entrant production lines - A deep learning approach
|
Zhou, F.-Y.;Wu, C.-H.;Yu, C.-J.; Zhou, F.-Y.; Wu, C.-H.; Yu, C.-J.; CHENG-HUNG WU |
| 臺大學術典藏 |
2020-02-27T07:43:41Z |
Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer
|
Luh K.-T.;Kuo S.-H.;Lin F.-Y.;WEN-JONE CHEN;Yu C.-J.;Yang P.-C.;Yuan A.; Yuan A.; Yang P.-C.; Yu C.-J.; WEN-JONE CHEN; Lin F.-Y.; Kuo S.-H.; Luh K.-T. |
| 臺大學術典藏 |
2020-02-27T07:43:40Z |
Quantification of VEGF mRNA expression in non-small cell lung cancer using a real-time quantitative reverse transcription-PCR assay and a comparison with quantitative competitive reverse transcription-PCR
|
Yang P.-C.;Kuo S.-H.;Lin F.-Y.;WEN-JONE CHEN;Luh K.-T.;Yu C.-J.;Yuan A.; Yuan A.; Yu C.-J.; Luh K.-T.; WEN-JONE CHEN; Lin F.-Y.; Kuo S.-H.; Yang P.-C. |
